Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

Lu,Qiang; Lv,Gang; Kim,Andre; Ha,Jong‑Myung; Kim,Suhkman

doi:10.3892/ol.2012.981

Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

Authors:
- Qiang Lu
- Gang Lv
- Andre Kim
- Jong‑Myung Ha
- Suhkman Kim
View Affiliations

Affiliations: Department of Orthopaedics, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Pharmaceutical Engineering, College of Medical Life Sciences, Silla University, Busan 617‑736, Republic of Korea, Department of Chemistry and Chemistry Institute for Functional Materials, Pusan National University, Busan 609‑735, Republic of Korea
Published online on: October 19, 2012 https://doi.org/10.3892/ol.2012.981
Pages: 201-207

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Recent studies have shown that extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) promotes adhesion, invasion and metastasis of malignant tumor cells. The aim of this study was to investigate the impact of EMMPRIN/CD147 expression on prognosis and its correlation with clinicopathological characteristics in patients with osteosarcoma. The expression of EMMPRIN/CD147 in 55 surgical specimens from patients with osteosarcoma at stage IIA or above, 15 non‑tumor rib bone tissues, three human osteosarcoma cell lines (Saos‑2, U‑2OS and MG‑63), the human osteoblast cell line HOB and the malignant melanoma cell line A375 were examined by immunohistochemistry, western blot analysis and ELISA, respectively. The potential association of the levels of EMMPRIN/CD147 expression in osteosarcoma specimens with the overall survival of patients was statistically analyzed. We found that the EMMPRIN/CD147 was expressed in 45 out of 55 osteosarcomas, with immunoreactivity primarily within the membrane and cytoplasm of tumor cells, but not in the non‑tumor bone tissues. We also observed that EMMPRIN/CD147 was expressed in Saos‑2, U‑2OS, MG‑63 and A375, but not in HOB cells. The levels of EMMPRIN/CD147 expression correlated positively with the pathological degree of osteosarcoma and negatively with the survival period of patients with osteosarcoma. The expression of EMMPRIN/CD147 is a potential factor in the development and prognosis of osteosarcoma and may be a novel therapeutic target of human osteosarcoma.

View Figures

View References

1	Clark JC, Dass CR and Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
2	Davicioni E, Wai DH and Anderson MJ: Diagnostic and prognostic sarcoma signatures. Mol Diagn Ther. 12:359–374. 2008. View Article : Google Scholar
3	Fagioli F, Biasin E, Mereuta OM, et al: Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplant. 41(Suppl 2): S131–S134. 2008. View Article : Google Scholar : PubMed/NCBI
4	Sakamoto A and Iwamoto Y: Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials. 3:228–231. 2008. View Article : Google Scholar : PubMed/NCBI
5	Wang LL: Biology of osteogenic sarcoma. Cancer J. 11:294–305. 2005. View Article : Google Scholar : PubMed/NCBI
6	Federman N, Bernthal N, Eilber FC and Tap WD: The multi-disciplinary management of osteosarcoma. Curr Treat Options Oncol. 10:82–93. 2009. View Article : Google Scholar
7	Hakuma N, Betsuyaku T, Kinoshita I, et al: High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers. Association with clinicopathological parameters. Oncology. 72:197–204. 2007. View Article : Google Scholar
8	Jia L, Wei W, Cao J, Xu H, Miao X and Zhang J: Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells. Ann Hematol. 88:753–760. 2009. View Article : Google Scholar : PubMed/NCBI
9	Aratake Y, Marutsuka K, Kiyoyama K, et al: EMMPRIN (CD147) expression and differentiation of papillary thyroid carcinoma: implications for immunocytochemistry in FNA cytology. Cytopathology. 21:103–110. 2009. View Article : Google Scholar : PubMed/NCBI
10	Chen T and Zhu J: Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol. 27:1185–1191. 2009. View Article : Google Scholar : PubMed/NCBI
11	Zhang C, Tu Z, Du S, Wang Y and Wang Q: Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma. Pathol Oncol Res. 16:47–53. 2010. View Article : Google Scholar
12	Buergy D, Fuchs T, Kambakamba P, et al: Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer. Cancer. 115:4667–4678. 2009. View Article : Google Scholar
13	Liang YX, He HC, Han ZD, et al: CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value. Cancer Invest. 27:788–793. 2009. View Article : Google Scholar : PubMed/NCBI
14	Han ZD, Bi XC, Qin WJ, et al: CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res. 15:369–374. 2009. View Article : Google Scholar : PubMed/NCBI
15	Ju XZ, Yang JM, Zhou XY, Li ZT and Wu XH: EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer. Clin Cancer Res. 14:494–501. 2008. View Article : Google Scholar : PubMed/NCBI
16	Sillanpaa S, Anttila M, Suhonen K, et al: Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol. 28:280–289. 2007. View Article : Google Scholar : PubMed/NCBI
17	Yang JM, O’Neill P, Jin W, et al: Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim. J Biol Chem. 281:9719–9727. 2006. View Article : Google Scholar : PubMed/NCBI
18	Zhu H, Evans B, O’Neill P, et al: A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells. Cancer Biol Ther. 8:1722–1728. 2009. View Article : Google Scholar : PubMed/NCBI
19	Bougatef F, Quemener C, Kellouche S, et al: EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood. 114:5547–5556. 2009. View Article : Google Scholar : PubMed/NCBI
20	Tang Y, Nakada MT, Kesavan P, et al: Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 65:3193–3199. 2005.
21	Zheng HC, Takahashi H, Murai Y, et al: Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer. 95:1371–1378. 2006. View Article : Google Scholar : PubMed/NCBI
22	Duivenvoorden WC, Hirte HW and Singh G: Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis. 17:27–34. 1999. View Article : Google Scholar : PubMed/NCBI
23	Quemener C, Gabison EE, Naimi B, et al: Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res. 67:9–15. 2007. View Article : Google Scholar : PubMed/NCBI
24	Riethdorf S, Reimers N, Assmann V, et al: High incidence of EMMPRIN expression in human tumors. Int J Cancer. 119:1800–1810. 2006. View Article : Google Scholar : PubMed/NCBI
25	Wang P, Xu TY, Guan YF, Su DF, Fan GR and Miao CY: Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 81:370–380. 2009. View Article : Google Scholar : PubMed/NCBI
26	Wang P, Xu TY, Guan YF, et al: Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol. 69:360–374. 2011. View Article : Google Scholar
27	Wang P, Guan YF, Du H, Zhai QW, Su DF and Miao CY: Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy. 8:77–87. 2012. View Article : Google Scholar : PubMed/NCBI
28	Wang P, Zhang RY, Song J, et al: Loss of AMP-activated protein kinase-alpha2 impairs the insulin-sensitizing effect of calorie restriction in skeletal muscle. Diabetes. 61:1051–1061. 2012. View Article : Google Scholar : PubMed/NCBI
29	Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 153:106–120. 1980.PubMed/NCBI
30	Enneking WF, Spanier SS and Goodman MA: Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am. 62:1027–1030. 1980.PubMed/NCBI
31	Picci P, Bacci G, Campanacci M, et al: Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 56:1515–1521. 1985. View Article : Google Scholar : PubMed/NCBI
32	Wang P, Yang FJ, Du H, et al: Involvement of leptin receptor long isoform (LepRb)-STAT3 signaling pathway in brain fat mass- and obesity-associated (FTO) downregulation during energy restriction. Mol Med. 17:523–532. 2011.PubMed/NCBI
33	Zhou Q, Zhu Y, Deng Z, Long H, Zhang S and Chen X: VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 20:13–19. 2011. View Article : Google Scholar : PubMed/NCBI
34	Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ and Li Y: The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother. 57:1367–1379. 2008. View Article : Google Scholar : PubMed/NCBI
35	Ishibashi Y, Matsumoto T, Niwa M, et al: CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer. 101:1994–2000. 2004. View Article : Google Scholar : PubMed/NCBI
36	Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J and Kikuchi M: Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 56:359–367. 2006. View Article : Google Scholar : PubMed/NCBI
37	Cheng MF, Tzao C, Tsai WC, et al: Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis Esophagus. 19:482–486. 2006. View Article : Google Scholar : PubMed/NCBI
38	Dean NR, Newman JR, Helman EE, et al: Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res. 15:4058–4065. 2009. View Article : Google Scholar : PubMed/NCBI
39	Kuang YH, Chen X, Su J, et al: RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Lett. 276:189–195. 2009. View Article : Google Scholar : PubMed/NCBI
40	Han ZD, He HC, Bi XC, et al: Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res. 160:260–267. 2010. View Article : Google Scholar : PubMed/NCBI